Kenvue Inc. (NYSE:KVUE) Shares Bought by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 13.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 383,049 shares of the company’s stock after acquiring an additional 45,800 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Kenvue were worth $6,964,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. Manchester Capital Management LLC grew its stake in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares in the last quarter. Mather Group LLC. acquired a new stake in shares of Kenvue in the first quarter valued at $28,000. Riverview Trust Co acquired a new stake in shares of Kenvue in the first quarter valued at $33,000. MV Capital Management Inc. grew its stake in shares of Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after buying an additional 642 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in shares of Kenvue in the first quarter valued at $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.5 %

Shares of NYSE KVUE opened at $23.02 on Friday. The company has a market capitalization of $44.08 billion, a price-to-earnings ratio of 29.51, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The business has a 50-day moving average of $20.92 and a two-hundred day moving average of $19.96. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.55.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. Kenvue’s revenue for the quarter was down .3% on a year-over-year basis. During the same period in the previous year, the business earned $0.32 EPS. On average, analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, August 14th. This is a boost from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.56%. Kenvue’s dividend payout ratio is 105.13%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on KVUE shares. Deutsche Bank Aktiengesellschaft lifted their price objective on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. UBS Group lifted their target price on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of Kenvue in a report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their target price on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Citigroup decreased their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $21.44.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.